Healthtech Pigeon Will we see an end to the GLP-1 gold rush?
Nov 23, 2025
Jessica Somauroo and Belle Taylor delve into the fascinating world of healthtech. They discuss Manual's impressive $120M funding to boost GLP-1 weight-loss services and explore the implications of non-dilutive funding strategies. The duo debates the shifting focus of men's clinics towards GLP-1 treatments, revealing investor trends. Plus, they highlight Clue's new integrations with popular wearables, showcasing how objective data can enhance cycle tracking. The conversation wraps up on a positive note regarding women's health.
AI Snips
Chapters
Transcript
Episode notes
A Garden Full Of Blue Tits
- Belle describes finding dozens of blue tits in her garden and then discovering feathers and a dead bird inside her home.
- She recounts her cat Miso likely catching the bird and calling the pet a 'stone cold killer.'
Non‑Dilutive Funding Changes Risk Dynamics
- General Catalyst used non-dilutive, revenue-linked financing to fund Manuel's GLP-1 scaling instead of taking equity.
- This shifts repayment risk onto revenue performance and lets Manuel avoid share dilution while enabling fast consumer growth.
GLP‑1 Gold Rush Is Reshaping Health Startups
- The GLP-1